Navigation Links
Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
Date:12/14/2010

of additional higher doses of LX2931 as an orally-delivered treatment for rheumatoid arthritis," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon.  "While we were disappointed by the unusually high placebo effect in this trial, we are encouraged by the excellent overall safety profile observed in the first test of this new mechanism of action in patients with RA."  

The company intends to commence discussions with potential pharmaceutical partners to pursue further development of LX2931 in rheumatoid arthritis.

Clinical Trial

The recently completed study was a 12-week, randomized, double-blind, placebo-controlled study in 208 patients on stable dose methotrexate with progressing rheumatoid arthritis. Patients were randomized to receive either placebo (n=49) or LX2931, 70 mg (n=55), 110 mg (n=54), or 150 mg (n=50), once daily for 12 weeks.  In addition to measurements to assess the drug's safety, efficacy endpoints included the primary endpoint, ACR20 at week 12, as well as secondary endpoints of ACR20, ACR50, ACR70 and DAS28 at weeks 4, 8 and 12.  The trial was conducted at sites within the United States and Eastern Europe.

About S1P Lyase and the Role of S1P in Autoimmune Disease

S1P lyase is responsible for the irreversible degradation of S1P, a biologically active lipid that can act as a second messenger in signal transduction pathways important for immune function.  Changes in local S1P concentrations and gradients in immune tissues can modify lymphocyte migration, inflammatory cell response, and affect barrier function of endothelial cells.  Inhibiting S1P lyase results in an increase in S1P levels, primarily in lymphoid tissues.  The physiological outcome of raising S1P levels in the lymphoid system is immune-modulation, which offers new opportunities for treating autoimmune and inflammatory
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft ... Company,s Phase 2 clinical trial.  This open-label study will ... GPX-150 (an investigational medication), in approximately 30 adults as ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 ...
(Date:1/22/2015)... MINNEAPOLIS, Jan. 22, 2015  Uroplasty, Inc. (NASDAQ: UPI ... markets innovative proprietary products to treat voiding dysfunctions, today ... ended December 31, 2014.  Global revenue for the ... $4.4 million, a new quarterly revenue record, as compared ...
(Date:1/22/2015)... 22, 2015  Profil Institute for Clinical Research, Inc., a ... announced today a new textbook,  Translational Research Methods for ... a leading global scientific publisher. The textbook ... for use in early phase clinical studies of new ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3
... 2, 2011 Reportlinker.com announces ... report is available in its ... Cardiology Devices: World Market Prospects ... http://www.reportlinker.com/p0663863/Interventional-Cardiology-Devices-World-Market-Prospects-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine Our ...
... 2, 2011 Syndax Pharmaceuticals, Inc ., a ... in a subset of patients from ENCORE 301, a ... entinostat in advanced breast cancer patients, will be presented ... for Cancer Research (AACR) Molecular Targets and Cancer Therapeutics ...
Cached Medicine Technology:Interventional Cardiology Devices: World Market Prospects 2011-2021 2Interventional Cardiology Devices: World Market Prospects 2011-2021 3Interventional Cardiology Devices: World Market Prospects 2011-2021 4Interventional Cardiology Devices: World Market Prospects 2011-2021 5Interventional Cardiology Devices: World Market Prospects 2011-2021 6Interventional Cardiology Devices: World Market Prospects 2011-2021 7Interventional Cardiology Devices: World Market Prospects 2011-2021 8Interventional Cardiology Devices: World Market Prospects 2011-2021 9Interventional Cardiology Devices: World Market Prospects 2011-2021 10Interventional Cardiology Devices: World Market Prospects 2011-2021 11Interventional Cardiology Devices: World Market Prospects 2011-2021 12Interventional Cardiology Devices: World Market Prospects 2011-2021 13Interventional Cardiology Devices: World Market Prospects 2011-2021 14Pharmacodynamic Data from Syndax Pharmaceutical's ENCORE 301 Study in Advanced Breast Cancer to be Highlighted at the AACR Molecular Targets and Cancer Therapeutics Conference 2011 2Pharmacodynamic Data from Syndax Pharmaceutical's ENCORE 301 Study in Advanced Breast Cancer to be Highlighted at the AACR Molecular Targets and Cancer Therapeutics Conference 2011 3
(Date:1/22/2015)... 22, 2015 Liberty University has received accreditation ... program from the Council for Accreditation of Counseling & ... Liberty’s Center for Counseling & Family Studies , is ... the university’s new School of Behavioral Sciences. Prior to the ...
(Date:1/22/2015)... 22, 2015 Gabe’s Chemo Duck Program is pleased ... first app ever created for kids with cancer. The Chemo Duck ... devices, is filled with enjoyable games to help children of all ... free app helps to keep kids entertained, educated and at ease ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 Angelweddingdress is a ... business invites its customers to follow it on Facebook, Twitter, ... a Valentine’s Day gift. Angelweddingdress draws a lottery every week. ... Sale to Feb. 28, 2015. Click Angelweddingdress homepage ...
(Date:1/22/2015)... 22, 2015 Juvent Sports ( http://www.juventsports.com ... 2015 PGA Merchandise Show to bestow a Juvent Sports ... amateur golfer, Arlene McKitrick. The award commemorated and congratulated ... tournament win. She won her first amateur tournament in ...
(Date:1/22/2015)... 22, 2015 For over 20 years, Dr. David ... and Vista area has treated just about every type of ... circumstances. And for those same twenty-plus years, the team at ... those injuries with the best possible doctor. With the ...
Breaking Medicine News(10 mins):Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
... hernia surgeries in 13 hours, 41 minutes and 19 seconds ... // ,The surgeon Dr J S Rajkumar, chairman, Lifeline ... surgeries in 24 hours. ,The patients on whom ... exercise was backed by a team of dedicated professionals and ...
... Recent studies conducted on bird flu vaccine has now established that ... bird flu crisis may not be as effective as it is ... the companies developing such a vaccine named as generic H5N1 and ... be in production by the end of the year, and is ...
... Heart and Stroke Foundation of Canada has issued a wake up ... in the advancement of heart health. // ,Dr. Beth ... that the rates of obesity in baby boomers have soared by ... inactive." ,Abramson feels that baby boomers, the group between ...
... of great joy and expectation as both the expectant mother ... women however are not able to experience the bliss due ... more than psychological distress. A few of the factors that ... special report. , Abuse during pregnancy: Abuse ...
... coffee, it as been found in a study that drinking coffee ... that consumption should be moderate. Its moderate consumption every day may ... ,Previous studies in US had linked drinking more than two cups ... of chronic liver disease. ,This new study by Harvard ...
... spurred by the inability or failure to ‘Gasp’. But now, ... probable cause of SIDS. // ,University of Bristol ... that are capable of producing nervous impulses on their ... ‘pacemakers.' ,The research team, led by Professor Julian Paton ...
Cached Medicine News:Health News:Do Women Die In Childbirth Because It Is More Preferable? 2Health News:Do Women Die In Childbirth Because It Is More Preferable? 3
Used to provide drainage of urine from the bladder. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Inte...
... Used for temporary ... ureteropelvic junction to the ... Supplied sterile in peel-open ... use. CAUTION: Periodic evaluation ...
Used for stenting the urethra during hypospadias or epispadias repair and to allow post-operative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
Used for stenting the urethra after hypospadias or epispadias repair and to provide post-operative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: